On Nov 05, major Wall Street analysts update their ratings for $Disc Medicine (IRON.US)$, with price targets ranging from $70 to $112.
Morgan Stanley analyst Jeffrey Hung upgrades to a buy rating, and adjusts the target price from $40 to $85.
Wells Fargo analyst Tiago Fauth maintains with a buy rating, and adjusts the target price from $75 to $91.
BMO Capital analyst Evan Seigerman maintains with a buy rating, and adjusts the target price from $70 to $112.
Raymond James analyst Danielle Brill maintains with a buy rating, and adjusts the target price from $50 to $110.
H.C. Wainwright analyst Douglas Tsao maintains with a buy rating, and maintains the target price at $70.
Furthermore, according to the comprehensive report, the opinions of $Disc Medicine (IRON.US)$'s main analysts recently are as follows:
The anticipation for accelerated market entry for Disc Medicine's bitopertin is growing, following positive feedback from an end-of-Phase 2 meeting, which could fast-track its approval based on the existing data. This development increases the likelihood of bitopertin reaching the market sooner and with more certainty. Should accelerated approval be obtained, it would align with more optimistic scenarios for the company's valuation.
Following a favorable regulatory update for bitopertin, the likelihood of its point-of-sale has been increased to 80%, with the anticipation that approval will be expedited using the data already available. This development is seen as a substantial positive, emphasizing the potential for bitopertin to be a genuinely disease-modifying treatment.
Here are the latest investment ratings and price targets for $Disc Medicine (IRON.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
